Haemonetics Corp.

HAE

NYSE; healthcare; SIC 3841, Surgical & Medical Instruments & Apparatus; CIK 0000313143

C

middle fifth of 369 graded peers in healthcare

rank 192 of 369; percentile 51.9; sampling error 2.5 points; lower is stronger

A B C D E

C, the tortoise



Scoreboard

Profitability	C percentile 49.3
Solvency	D percentile 68.6
Growth and financing	B percentile 28.0
Reliability	0.91 AUC filers with $591M to $2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$591M to $2.67B assets total assets $2.4B
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered not computable: distress
Inputs computable	11 of 14
Graded from	filings received through May 20, 2026 176 days before the rescan; latest periodic filing 10-Q received Nov 5, 2026
Last close	$120.67 2026-11-11; market equity $5.5B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received May 20, 2026

Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our innovative solutions addressing critical medical needs include a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers; and products to enable blood centers to collect in-demand blood components. When used in this report, the terms "we," "us," "our," "Haemonetics" and the "Company" mean Haemonetics Corporation.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 49.3						
Gross profitability	32.9%	32.3%		44.8	365	2026-03-28
Return on invested capital	6.7%	9.3%		56.2	74	2026-03-28
Accruals ratio	(8.1%)	(6.6%)		47.9	801	2026-03-28

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Gross margin stability, five years	2.8 pts	2.8 pts	48.5	242	2026-03-28
Solvency, sleeve percentile 68.6					
Twelve-month failure probability	not computable	0.08%			
liabilities and a nearby cover-page share count are required at 2026-09-26					
Altman Z double-prime	not computable	(0.35)			
one or more required annual facts are missing					
Net debt to EBITDA	4.56x	1.82x	81.1	75	2026-03-28
Interest coverage	not computable	(4.51x)			
interest expense must exceed $100,000					
Current ratio	2.95x	2.95x	56.1	827	2026-03-28
Growth and financing, sleeve percentile 28.0					
Revenue growth, three-year compound	4.5%	10.1%	61.6	412	2026-03-28
Free cash flow growth, three-year compound	47.2%	11.0%	14.9	95	2026-03-28
Reinvestment rate	140.2%	37.1%	24.0	105	2026-03-28
Asset growth, three years	7.4%	2.2%	36.6	695	2026-03-28
Net share issuance, one year	(5.4%)	2.5%	3.0	628	2026-05-15

Among 369 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
187	RadNet, Inc. (RDNT)	50.5	C	
188	Neuroone Medical Technologies Corp. (NMTC)	50.8	C	short runway, fortress balance sheet
189	Recursion Pharmaceuticals, Inc. (RXRX)	51.1	C	dilution, fortress balance sheet
190	Schrodinger, Inc. (SDGR)	51.4	C	
191	Solventum Corp. (SOLV)	51.6	C	
192	Haemonetics Corp. (HAE)	51.9	C	
193	Zai Lab Ltd. (ZLAB)	52.2	C	
194	Perrigo Co. plc (PRGO)	52.4	C	
195	Nexgel, Inc. (NXGL)	52.9	C	late filer
196	Nexgel, Inc. (NXGLW)	52.9	C	late filer
197	Aveanna Healthcare Holdings, Inc. (AVAH)	53.3	C	

What the price implies

at the 2026-11-11 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	110.6%	(1.9%)	92
Distance from 52-week high	(5.4%)	(27.8%)	78
EBIT to enterprise value	2.5%	(1.6%)	64
Free cash flow yield	4.7%	(1.0%)	82
Book value to price	0.16	0.27	35
Sales to price	0.24	0.29	44
Composite equity issuance, five years	(11.2%)	20.8%	15

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Relative strength against the sector, log excess return	0.58	(0.19)	92

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score 6 of 9, period end 2026-03-28	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	pass
Gross margin improved	pass
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$260.7M
Operating cash flow, four quarters	$344.9M
Months of runway	not finite
Days since last periodic filing	7 (10-Q received Nov 5, 2026)
Median daily dollar volume, 63 sessions	$63.6M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$787.6M	2026-03-28	2026-05-20	10-K	26-000050
2	assets	us-gaap:Assets	$2.4B	2026-03-28	2026-05-20	10-K	26-000050
3	operating income	us-gaap:OperatingIncomeLoss	$156.7M	2026-03-28	2026-05-20	10-K	26-000050
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$128.0M	2026-03-28	2026-05-20	10-K	26-000050
5	income tax	us-gaap:IncomeTaxExpenseBenefit	$30.7M	2026-03-28	2026-05-20	10-K	26-000050
6	total debt	us-gaap:LongTermDebt	$1.2B	2026-03-28	2026-05-20	10-K	26-000050
7	book equity	us-gaap:StockholdersEquity	$796.3M	2026-03-28	2026-05-20	10-K	26-000050
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$245.4M	2026-03-28	2026-05-20	10-K	26-000050
9	total debt	us-gaap:LongTermDebt	$1.2B	2025-03-29	2025-05-21	10-K	25-000025
10	book equity	us-gaap:StockholdersEquity	$820.8M	2025-03-29	2026-05-20	10-K	26-000050
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$306.8M	2025-03-29	2026-05-20	10-K	26-000050
12	net income	us-gaap:NetIncomeLoss	$97.3M	2026-03-28	2026-05-20	10-K	26-000050
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$293.2M	2026-03-28	2026-05-20	10-K	26-000050
14	assets	us-gaap:Assets	$2.5B	2025-03-29	2026-05-20	10-K	26-000050
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.3B	2026-03-28	2026-05-20	10-K	26-000050
16	gross profit	us-gaap:GrossProfit	$749.0M	2025-03-29	2026-05-20	10-K	26-000050
17	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.4B	2025-03-29	2026-05-20	10-K	26-000050
18	gross profit	us-gaap:GrossProfit	$691.5M	2024-03-30	2026-05-20	10-K	26-000050
19	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.3B	2024-03-30	2026-05-20	10-K	26-000050
20	gross profit	us-gaap:GrossProfit	$615.1M	2023-04-01	2025-05-21	10-K	25-000025
21	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAs...	$1.2B	2023-04-01	2025-05-21	10-K	25-000025
22	gross profit	us-gaap:GrossProfit	$505.5M	2022-04-02	2024-05-20	10-K	24-000020
23	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAs...	$993.2M	2022-04-02	2024-05-20	10-K	24-000020
24	depreciation amortization	us-gaap:Depreciation	$61.2M	2026-03-28	2026-05-20	10-K	26-000050
25	operating income	us-gaap:OperatingIncomeLoss	$110.5M	2011-04-02	2013-05-20	10-K	13-000085
26	interest expense	us-gaap:InterestExpense	$6,000	2011-04-02	2011-05-26	10-K	11-054481
27	current assets	us-gaap:AssetsCurrent	$834.9M	2026-03-28	2026-05-20	10-K	26-000050
28	current liabilities	us-gaap:LiabilitiesCurrent	$282.6M	2026-03-28	2026-05-20	10-K	26-000050
29	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$32.8M	2026-03-28	2026-05-20	10-K	26-000050
30	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$181.7M	2025-03-29	2026-05-20	10-K	26-000050

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

31	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$39.3M	2025-03-29	2026-05-20	10-K	26-000050
32	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$181.8M	2024-03-30	2026-05-20	10-K	26-000050
33	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$38.1M	2024-03-30	2026-05-20	10-K	26-000050
34	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$273.1M	2023-04-01	2025-05-21	10-K	25-000025
35	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$191.3M	2023-04-01	2025-05-21	10-K	25-000025
36	current assets	us-gaap:AssetsCurrent	$935.0M	2025-03-29	2026-05-20	10-K	26-000050
37	current liabilities	us-gaap:LiabilitiesCurrent	$578.1M	2025-03-29	2026-05-20	10-K	26-000050
38	assets	us-gaap:Assets	$2.2B	2024-03-30	2025-05-21	10-K	25-000025
39	assets	us-gaap:Assets	$1.9B	2023-04-01	2024-05-20	10-K	24-000020
40	shares outstanding	dei:EntityCommonStockSharesOutstanding	45,445,983	2026-05-15	2026-05-20	10-K	26-000050
41	shares outstanding	dei:EntityCommonStockSharesOutstanding	48,036,996	2025-05-16	2025-05-21	10-K	25-000025

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.